Prentice Capital Management’s Immunome IMNM Stock Holding History

Prentice Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-112,131	Closed	-$1.2M	–	24
2023 Q4	$1.2M	Hold	112,131	–	–	2.79%	12
2023 Q3	$936K	Hold	112,131	–	–	2.88%	11
2023 Q2	$887K	Sell	112,131 -319,773	-74%	-$1.75M	2.83%	16
2023 Q1	$2.16M	Sell	431,904 -66,241	-13%	-$324K	4.62%	8
2022 Q4	$1.1M	Sell	498,145 -293,676	-37%	-$1.18M	1.2%	21
2022 Q3	$3.52M	Hold	791,821	–	–	2.61%	13
2022 Q2	$2.54M	Sell	791,821 -500	-0.1%	-$1.82K	1.04%	18
2022 Q1	$4.5M	Sell	792,321 -14,200	-2%	-$106K	1.07%	21
2021 Q4	$10.5M	Buy	806,521 +289,341	+56%	+$5.16M	2.26%	16
2021 Q3	$12.6M	Hold	517,180	–	–	3.18%	13
2021 Q2	$8.95M	Buy	517,180 +185,185	+56%	+$4.09M	2.14%	19
2021 Q1	$11.2M	Sell	331,995 -84,672	-20%	-$2.1M	3.49%	11
2020 Q4	$4.03M	Buy	+416,667	New	+$4.86M	1.09%	17

Other funds holding IMNM

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Prentice Capital Management's IMNM Position: Q1 2024 in Review

Prentice Capital Management sold out of Immunome (IMNM) in Q1 2024, closing a stake of 112,131 shares — an estimated $1.2M sold.

Prentice Capital Management first reported a position in IMNM in Q4 2020 and held it in 13 quarters. The position peaked at $12.6M in Q3 2021. 104 funds tracked by Wall St. Rank hold IMNM as of Q1 2024.

Prentice Capital Management reported no remaining Immunome position as of Q1 2024 after selling out during the quarter.
Prentice Capital Management sold 112,131 Immunome shares in Q1 2024, an estimated $1.2M.
Prentice Capital Management first reported a position in Immunome in Q4 2020 and held it in 13 quarters.
Prentice Capital Management's Immunome position peaked at $12.6M in Q3 2021.
104 funds tracked by Wall St. Rank held Immunome as of Q1 2024.

Based on Prentice Capital Management's 13F filing for Q1 2024, filed 15 May 2024.